RD13-02

Phase 1Biologic

IInstitute of Hematology & Blood Diseases Hospital, China

RD13-02 is one of 21 biologic programs targeting Severe Aplastic Anemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Severe Aplastic AnemiaRecruiting

Severe Aplastic AnemiaPhase 1

Recruiting

Competition

Competitive Landscape

23 competitors in Severe Aplastic Anemia

#DrugCompanyPhaseTrials

Neoral

Novartis

Approved

13 2

Fludara

Sanofi

Phase 3

11 3

Promacta

GSK

Phase 3

6 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

16 5

Doptelet

Atgam

8 7

Cellcept

Roche

Phase 2

3 8

Rabbit ATG

Novartis

Phase 3

3 9

Rituxan

Roche

Phase 2

1 10

Romiplostim N01

Qilu Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Severe Aplastic Anemia

NCT06622694

Clinical

Trials by Indication[1]

Severe Aplastic Anemia1 trial

CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT06622694·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RD13-02. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RD13-02 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RD13-02. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Hematology & Blood Diseases Hospital, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: IInstitute of Hematology & Blood Diseases Hospital, China

RD13-02

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Severe Aplastic Anemia1 trial

References

Drug Info

Quick Facts

Related News